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Abstract
Objectives This study investigated the differences in the
incidence and severity of adverse drug events (ADEs) in
pediatric patients with and without cancer.
Methods We used data from the Japan Adverse Drug
Events Study for pediatrics, a cohort study enrolling
pediatric inpatients at two tertiary care teaching hospitals in
Japan. ADEs were identified by on-site review of all
medical charts, incident reports, and prescription queries
by pharmacists. Two independent physicians reviewed all
potential ADEs and classified ADEs in terms of severity
and class of causative medication. We compared the inci-
dence and characteristics of ADEs between pediatric can-
cer patients and non-cancer patients.
Results We enrolled 1189 patients during the study period,
27 with cancer and 1162 without cancer. We identified 480
ADEs in 234 patients (20%): 191 ADEs among 21 cancer
patients and 289 ADEs among 213 non-cancer patients (7.1
per patient vs. 0.25 per patient, respectively; p\ 0.0001).
The most common medications associated with ADEs in
cancer patients were antitumor agents; in contrast, medi-
cations associated with fatal or life-threatening ADEs in
cancer patients were most often sedatives (25%) and blood
products (25%). Medications associated with fatal or life-
threatening ADEs among non-cancer patients were most
often sedatives (15%). The percentages of fatal or life-
threatening ADEs in cancer patients and non-cancer
patients were 2.1 and 4.5%, respectively.
Conclusions Pediatric patients with cancer have a higher
risk for ADEs. Although the overall severity was similar
between patients with and without cancer, the most com-
mon classes of causative medication and medications
associated with a higher rate of severe ADEs differed.
Application of this information may help minimize the
impact of ADEs in pediatric patients.
Key Points
Adverse drug events occurred in pediatric patients
with cancer 28 times more frequently than in those
without cancer.
As expected, the medications most commonly
associated with adverse drug events in pediatric
patients with cancer were antitumor agents, but fatal
or life-threatening events due to such medications
were rare (0.7%).
The category of causative medication and severity of
adverse drug events differed between pediatric
patients with cancer and without cancer.
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1 Introduction
Adverse drug events (ADEs) are injuries due to medication
use. ADEs represent a serious problem in healthcare
because they are the most frequent cause of injuries due to
medical care in hospitals in developed countries [1, 2]. In
Japan, the JADE (Japan Adverse Drug Events) study, a
multicenter cohort study, was conducted to estimate the
epidemiology of ADEs in several settings [3]. In both
Japan and in Western countries, ADEs have been associ-
ated with substantial increases in morbidity and mortality
[1, 3–5]. Patients who need chemotherapy often experience
ADEs as the result of antitumor agents [6]. Pediatric
inpatients are vulnerable to ADEs because they often
cannot describe their symptoms and have small metabolic
reserves [7, 8]. In particular, pediatric cancer patients
receiving antitumor agents are at high risk for ADEs
because of the nature of the patients and drugs involved
[9, 10].
To examine the epidemiology of ADEs in pediatric
inpatients, we conducted the JADE study for pediatric
patients [11]. As a sub-study, we analyzed differences in
ADEs between pediatric patients with and without cancer
and evaluated the causes, symptoms, and severity of the
ADEs.
2 Methods
2.1 Study Design and Patient Population
This study was based on the data from the JADE study
for pediatric inpatients, which was a historical cohort
study performed in two tertiary care teaching hospitals in
Japan. The details of the study have been described
elsewhere [11]. Briefly, we included all patients aged
B15 years admitted to any ward, including the neonatal
intensive care unit (NICU) and pediatric intensive care
unit (ICU), and patients aged[15 years admitted to any
pediatric ward over a 3-month period in 2009. Because
some adult patients with congenital or metabolic diseases
were cared for by pediatricians from a young age, such
patients were included in this cohort study based on the
protocol. We excluded neonates in well-baby nurseries
from this study because they were healthy and not cared
for by pediatricians. If neonates had a problem such as
temporary dyspnea or mild cyanosis of the limbs at birth,
they were admitted to the NICU and cared for by
neonatologists. We included these neonates in this study.
We categorized the age groups as follows: neonates
(aged \1 month), infants (1 month to \1 year),
preschoolers (1 year to \7 years), school-aged children
(7 to\13 years), teenagers (13 to\19 years), and adults
(C19 years).
The institutional review boards of the two participating
hospitals approved the study. Because all data were
obtained as part of routine daily practice, the institutional
review boards waived the need for informed consent.
2.2 Definitions
The primary outcome of the study was the occurrence of
ADEs, which we compared between pediatric patients with
andwithout cancer. Cancer patientswere defined as thosewho
were diagnosed with any malignant tumor or those who had a
tumor and were receiving antitumor agents. Non-cancer
patients included those with benign or other tumors. We used
validatedmethodology for the classification ofADEs [12].An
ADE was defined as a health injury occurring because of
medication use. For example, nausea or vomiting in a patient
receiving an antitumor agent was considered an ADE. We
categorized the severity ofADEs as follows: fatal (resulting in
death), life-threatening (requiring transfer to the ICU or
causing anaphylactic shock), serious (neutropenia requiring a
special protective environment, cutaneous lesions requiring
therapy, gastrointestinal bleeding, altered mental status,
excessive sedation, increased creatinine level, or decreased
blood pressure), or significant (rash, diarrhea, or nausea).
Categories of ADE symptoms included bleeding; central
nervous system; allergic or skin reaction; liver or metabolic
dysfunction; cardiovascular; gastrointestinal; renal; respira-
tory; bone marrow suppression or cytopenia; and other.
We categorized medications as follows: antihistamines,
antibiotics, antitumor agents, adrenaline/anticholinergics,
blood products, hematopoietic drugs, anticoagulants,
diuretics/cardiovascular agents, antipyretic analgesics/
nonsteroidal anti-inflammatory drugs (NSAIDs), anticon-
vulsants, sedatives, antipsychotics, diagnostic drugs/elec-
trolytes and fluids/others, antitussives, ophthalmic/
otolaryngologic/dermatologic drugs, laxatives, local anes-
thetics, corticosteroids, hormones/insulin, aminophylline,
and peptic ulcer drugs. Antitussives did not include codeine
but did include expectorants, and sedatives did not include
narcotics or opiates. Because doses for pediatric patients
were generally determined by body weight, and the stan-
dard doses varied between drugs, we did not account for
dose in the analyses.
2.3 Data Collection and Review Process
Trained reviewers based at each participating hospital
reviewed all medical charts, laboratory results, incident
reports, and prescription queries from pharmacists. The
trained reviewers included a board-certified pediatrician,
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pediatric nurses, and a dietitian; the pediatrician trained all
reviewers in a standard manner, as reported elsewhere [12].
Reviewers collected the characteristics and administrative
data for all patients enrolled in the cohort and identified
potential ADEs and associated details, such as detailed
symptoms and drug name, dose, route, and class.
After data collection, two independent physician
reviewers assessed, in a standard manner, whether any
potential ADEs should be classified as ADEs [12]. Briefly,
the reviewers summarized and discussed many aspects,
including preceding drugs, other causative conditions
occurring during hospitalization, previous literature
reports, alleviation after discontinuation of drug, repeated
symptoms when the same drug was re-introduced, and so
on. They classified the severity, symptoms, and class of
medication involved in ADEs. When disagreement arose
over classification of an event, the reviewers reached
consensus through discussion. Uncertain symptoms or
those for which consensus was not reached were excluded
from the ADEs.
2.4 Statistical Analyses
Categorical variables regarding patient characteristics are
reported as numbers and percentages. A Chi squared test
was used to compare patients with and without cancer. We
also constructed a logistic regression model for cancer
patients who developed ADEs, adjusting for the age group
and admission to an ICU. The likelihood of ADEs was
expressed as an odds ratio (OR) and its 95% confidence
interval (CI). The ADE rate per 100 patients, ADE severity,
and ratio of ADE severity for each drug were compared
between cancer and non-cancer patients; the Chi squared
test was used for categorical variables.
We carried out all analyses using JMP 12.0 software
(SAS Institute Inc., Cary, NC, USA). Two-tailed p values
\0.05 were considered statistically significant.
3 Results
3.1 Patient Characteristics
Among the 1189 patients included in the JADE study for
pediatrics, 480 ADEs occurred in 234 (20%) patients.
Among the different age categories, there were 252 (21%)
neonates, 174 (15%) infants, 465 (39%) preschoolers, 189
(16%) school-aged children, 98 (8%) teenagers, and 11
(1%) adults (Table 1). The age of adults ranged from 20 to
42 years.
Antibiotics (61%), antipyretic analgesics/NSAIDs
(32%), adrenaline/anticholinergics (26%), and antitussives
(26%) were the three most frequent classes of prescribed
medication on admission.
3.2 Comparison of Cancer Patients and Non-Cancer
Patients
In all, we included 27 cancer patients and 1162 non-cancer
patients in this study. One patient with teratoma and
another with optic glioma were categorized as cancer
patients because they received chemotherapy during the
hospitalization. Patients with cancer had more operations
and received antitumor agents or anticoagulants more often
than those without cancer (Table 1). On the other hand,
patients without cancer more often received adrenaline/
anticholinergics and antipyretic analgesics/NSAIDs.
Overall, 191 ADEs occurred in 21 cancer patients and 289
ADEs occurred in 213 non-cancer patients. The ADE rate
per 100 patients in cancer patients was 707 compared with
25 in non-cancer patients (p\ 0.0001). The adjusted OR of
ADEs among patients with cancer was 12.3 (95% CI
4.9–31.1) compared with patients without cancer.
The severity of ADEs in cancer patients was similar to
that in non-cancer patients (p = 0.13). The percentages of
fatal or life-threatening ADEs in cancer patients and non-
cancer patients were 2.1 and 4.5%, respectively (Fig. 1).
Among 191 ADEs in cancer patients, 149 (78%) were
associated with antitumor agents, 13 (7%) with corticos-
teroids, ten (5%) with antibiotics, and eight (4%) with
sedatives. In contrast, among 289 ADEs in non-cancer
patients, 135 (47%) were associated with antibiotics, 52
(18%) with sedatives, 21 (7%) with corticosteroids, and 13
(4%) with antipyretic analgesics/NSAIDs (Fig. 2).
In contrast to all ADEs, medications with a high fre-
quency of fatal or life-threatening ADEs among cancer
patients included sedatives (25%) and blood products
(25%); those among non-cancer patients included antico-
agulants (50%), sedatives (15.4%), and hormones/insulin
(50%), although the sample size was small (Fig. 3).
3.3 Adverse Drug Events (ADEs) Due to Antitumor
Agents
Among the 27 cancer patients, 149 ADEs occurred in 18
patients due to antitumor agents, for a rate of 552 per 100
patients. Analysis of the severity of ADEs due to antitumor
agents showed there was one (0.7%) life-threatening ADE,
43 (29%) serious ADEs, and 105 (70%) significant ADEs.
Symptom categories of ADEs due to antitumor agents
included five (3%) bleeding, eight (5%) central nervous
system, 11 (8%) allergic or skin reaction, 17 (11%) liver or
metabolic dysfunction, one (0.7%) cardiovascular, 58
(39%) gastrointestinal, four (3%) renal, one (0.7%)
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respiratory, 37 (25%) bone marrow suppression or
cytopenia, and seven (5%) other.
4 Discussion
The rate of ADEs in pediatric patients with cancer was
higher than in those without cancer—cancer patients had
seven ADEs on average. Although the sample size of
cancer patients was small, the overall severity of the ADEs
seemed similar between cancer and non-cancer patients.
While most of the ADEs for cancer patients were caused by
antitumor agents, most of the fatal or life-threatening ADEs
were caused by sedatives and blood products. The classes
of drugs causing fatal or life-threatening ADEs seemed to
differ between pediatric patients with cancer and those
without.
Data on ADEs among pediatric patients with cancer are
sparse. For example, Takata et al. [13] found that pediatric
patients with cancer more frequently experienced ADEs
and that hematology and oncology wards had a higher
incidence of ADEs. In this study, while we found that
Table 1 Patient characteristics
Characteristics All
(n = 1189)
Cancer patients
(n = 27)
Non-cancer patients
(n = 1162)
p value
Age
Neonate (\1 month) 252 (21) 0 (0) 252 (22) 0.02
Infant (1 month to\1 year) 174 (15) 5 (19) 169 (15)
Preschooler (1 to\7 years) 465 (39) 12 (44) 453 (39)
School-aged (7 to\13 years) 189 (16) 4 (15) 185 (16)
Teenager (13 to\19 years) 98 (8) 6 (22) 92 (8)
Adult (C19 years) 11 (1) 0 (0) 11 (1)
Sex
Male 649 (55) 18 (67) 631 (54) 0.2
Surgery during hospitalization 294 (25) 14 (52) 280 (24) 0.001
Drug after admission
Antihistamines 244 (21) 8 (30) 236 (20) 0.24
Antibiotics 727 (61) 19 (70) 708 (61) 0.32
Antitumor agents 4 (0.3) 3 (11) 1a (0.1) \0.0001
Adrenaline/anticholinergics 309 (26) 1 (4) 308 (27) 0.006
Blood products 28 (2) 0 (0) 28 (2) 1.0
Hematopoietic drugs 24 (2) 0 (0) 24 (2) 1.0
Anticoagulants 86 (7) 6 (22) 80 (7) 0.002
Diuretics/cardiovascular agents 119 (10) 2 (7) 117 (10) 1.0
Antipyretic analgesics/NSAIDs 383 (32) 3 (11) 380 (33) 0.02
Anticonvulsants 173 (15) 7 (26) 166 (14) 0.09
Sedatives 69 (6) 4 (15) 65 (6) 0.07
Antipsychotics 13 (1) 0 (0) 13 (1) 1.0
Diagnostic drugs/electrolytes and fluids/others 967 (81) 21 (78) 946 (81) 0.63
Antitussives 305 (26) 3 (11) 302 (26) 0.12
Ophthalmic/otolaryngologics/dermatologics 154 (13) 2 (7) 152 (13) 0.56
Laxatives 191 (16) 6 (22) 185 (16) 0.38
Local anesthetics 39 (3) 2 (7) 37 (3) 0.22
Corticosteroid 138 (12) 6 (22) 132 (11) 0.08
Hormones/insulin 24 (2) 2 (7) 22 (2) 0.1
Aminophylline 67 (6) 0 (0) 67 (6) 0.4
Peptic ulcer drugs 111 (9) 2 (7) 109 (9) 1.0
Data are presented as n (%) unless otherwise indicated
ADEs adverse drug events, NSAIDs non-steroidal anti-inflammatory drugs
a One patient without cancer received an antitumor agent to treat a non-malignant condition
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ADEs occurred frequently in pediatric cancer patients, the
rate of fatal or life-threatening ADEs was much lower
(2.1%). A systematic review of studies in pediatric patients
with leukemia reported treatment-related mortality (which
should be considered an ADE) of 3.6% [14], which is
similar to the rate in our data. The higher incidence of all
ADEs but comparable risk for fatality in the current study
might be because we proactively collected all ADEs in a
standard manner, and most ADEs were minor injuries.
The prevalence of ADEs by medication classes differs
between settings. For example, one study in hospitalized
adults found that 32% of ADEs due to antitumor agents
were fatal [15]. Moreover, another study [16] in patients
with unplanned cancer admissions found that 13% had
Fig. 1 Comparison of adverse
drug event severity between
cancer patients and non-cancer
patients. ADEs adverse drug
events
Fig. 2 Causative drugs of adverse drug events. ADEs adverse drug events, NSAIDs non-steroidal anti-inflammatory drugs
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ADEs. Furthermore, Nazer et al. [15] reported that, among
oncology patients, the medications most commonly asso-
ciated with an ADE requiring ICU admission were anti-
tumor agents, analgesics, and anticoagulants. In contrast, in
the current study in the pediatric setting, only one (0.7%)
fatal or life-threatening ADE due to antitumor agents
occurred, although the number of patients evaluated was
small.
As sepsis from febrile neutropenia (FN) sometimes
causes a fatal ADE, it is an important type of ADE due to
antitumor agents. Admittance for FN has been reported to
be 4.4 per 100 oncology admissions [16], with an annual
incidence of 19.4 cases of FN per 1000 oncology admis-
sions [17]. Because we classified such symptoms as bone
marrow suppression rather than FN, the incidence of bone
marrow suppression was higher, at 205 per 100 cancer
patients. This provides additional evidence that antitumor
agents as a class are most commonly associated with
ADEs.
We must recognize that drugs with great benefit gen-
erally have a high rate of ADEs. Moreover, differences
were apparent between the drug classes causing ADEs in
cancer patients compared with in non-cancer patients. Such
differences should be noted to assist with awareness and
proper monitoring when these drugs are administered.
Although the frequency of ADEs due to antitumor agents
was high, the high risk for fatal or life-threatening ADEs
with other drugs, namely blood products and sedatives,
should also be considered for pediatric patients with
cancer.
Our study has several limitations. First, the number of
pediatric patients with cancer was much smaller than that
without cancer, so we could not draw definitive
conclusions. On the other hand, this study was conducted at
a daily clinical setting, and the findings reflect real-world
data. Second, we conducted this pediatric study at two
tertiary care teaching hospitals. Therefore, the results are
not generalizable to non-tertiary care teaching hospitals, in
which most children receive medical care in Japan. Third,
some ADEs may not have been noted in the charts and may
thus not have been detected, potentially resulting in
underestimation of ADEs. In addition, because many ADEs
due to antitumor agents are well-known and noticeable,
other ADEs in cancer patients might have been overlooked.
However, more robust alternatives to measure ADEs have
not yet been developed. Finally, the classification of ADEs
seemed arbitrary, and many symptoms were difficult to
classify as ADEs or other conditions. However, we deter-
mined the most likely causative drug based on the histor-
ical evidence from the literature, and this method is the best
one currently available.
5 Conclusion
Pediatric patients with cancer had more frequent ADEs
than did those without cancer. While most ADEs in cancer
patients were caused by antitumor agents, other medica-
tions caused the greatest proportion of fatal or life-threat-
ening ADEs. The overall severity of ADEs in patients with
and without cancer was similar. Nonetheless, knowing
which medication classes have higher risks for ADEs in
pediatric patients with and without cancer may help pro-
viders more carefully use those medications and monitor
patients, which may in turn help to minimize the impact of
ADEs in pediatric patients overall.
Fig. 3 Severity of adverse drug events in a cancer and b non-cancer patients. ADEs adverse drug events, NSAIDs non-steroidal anti-
inflammatory drugs
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